(d)-(e) During the last five years, none of the Reporting Persons has been (A) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (B) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

James N. Blue is a citizen of the United States.

On October 2, 2017, the Issuer and Synchron executed an investment agreement (the "Investment Agreement") providing for the purchase of Common Shares of the Issuer. Pursuant to the Investment Agreement, Synchron acquired (x) the right to designate two directors to fill vacancies on the Board of Directors of the Issuer and (y) 26,650,000 Common Shares of the Issuer (the "Acquired Shares"), which constituted approximately 33.5% of the fully-diluted Common Shares issued and outstanding as of the date of the transaction, for $4,752,000 in cash, including a $500,000 preliminary payment made on August 18, 2017 pursuant to a term sheet executed between the Issuer and an affiliate of Synchron (the "Purchase Price"). The Issuer and Synchron also executed an intellectual property rights agreement, pursuant to which the Issuer has granted Synchron certain rights to the Issuer's intellectual property relating to rare earth processing and separation. The Issuer also granted Synchron an option (the "Option") to purchase Common Shares of the Issuer that constitute 15.496667690889% of the fully diluted Common Shares of the Issuer immediately after the exercise of the Option (the "Option Shares") at a total exercise price of $5,040,000 in cash (the "Option Exercise Price"). On October 14, 2019, Synchron exercised the Option in full by delivering an exercise notice to the Issuer pursuant to the Investment Agreement and therefore acquired 24,175,000 Common Shares from the Issuer for the Option Exercise Price (such transaction, the "2019 Option Exercise"). On November 12, 2021, the Issuer commenced a rights offering for its Common Shares (the "2021 Rights Offering"), which expired on December 8, 2021. Synchron was advised that the Common Shares issued pursuant to the 2021 Rights Offering were distributed on December 16, 2021 to shareholders that had exercised their subscription rights, it being confirmed that Synchron had purchased 65,531,925 Common Shares of the Issuer for a total price of $15,727,662 in cash (such transaction, the "2021 Subscription"). On February 16, 2024, the Issuer commenced another rights offering for its Common Shares (the "2024 Rights Offering"), which expired on March 11, 2024. Synchron was advised that the Common Shares issued pursuant to the 2024 Rights Offering were distributed on March 15, 2024 to shareholders that exercised their subscription rights, it being confirmed that Synchron purchased 244,383,591 Common Shares of the Issuer for a total price of $29,326,030 in cash (such transaction, the "2024 Subscription"). On January 6, 2026, the Issuer commenced another rights offering for its Common Shares (the "2026 Rights Offering"), which expired on January 30, 2026. Synchron was advised that the Common Shares issued pursuant to the 2026 Rights Offering were distributed on March 4, 2026 to shareholders that exercised their subscription rights, it being confirmed on March 10, 2026 that Synchron purchased 100,149,060 Common Shares of the Issuer for a total price of $24,035,774.40 in cash (such transaction, the "2026 Subscription"). The Common Shares acquired in the 2026 Subscription, together with the Common Shares acquired in the 2024 Subscription, the Common Shares acquired in the 2021 Subscription, the Option Shares and the Acquired Shares, constitute approximately 71.4% of the fully diluted Common Shares assuming (i) 516,134,712 Common Shares of the Issuer issued and outstanding as of January 30, 2026 (as disclosed in the Issuer's prospectus supplement filed with the SEC in connection with the 2026 Rights Offering on February 6, 2026 (the "Prospectus Supplement")) and (ii) 129,033,678 Common Shares of the Issuer were issued in connection with the 2026 Rights Offering (as contemplated by the Prospectus Supplement). The source of the Purchase Price and the Option Exercise Price was available cash and cash equivalents of Synchron.

See Item 3 above.

(a)-(b) Synchron is the beneficial owner of 460,889,576 Common Shares of the Issuer, including 26,650,000 Acquired Shares (which were issued in connection with the Investment Agreement transaction described in the Existing Schedule 13D), 24,175,000 Option Shares (which were issued in connection with the 2019 Option Exercise), 65,531,925 Common Shares acquired in the 2021 Rights Offering, 244,383,591 Common Shares acquired in the 2024 Rights Offering and 100,149,060 Common Shares acquired in the 2026 Rights Offering, constituting, in the aggregate, approximately 71.4% of the Common Shares of the Issuer assuming (i) 516,134,712 Common Shares of the Issuer issued and outstanding as of January 30, 2026 (as disclosed in the Prospectus Supplement) and (ii) 129,033,678 Common Shares of the Issuer were issued in connection with the 2026 Rights Offering (as contemplated by the Prospectus Supplement). Synchron has the sole voting and dispositive power over the Acquired Shares, the Option Shares, the Common Shares acquired in the 2021 Rights Offering, the Common Shares acquired in the 2024 Rights Offering and the Common Shares acquired in the 2026 Rights Offering. Because each of General Atomic Technologies Corporation, Tenaya and Mr. Blue may be deemed to control Synchron, each of General Atomic Technologies Corporation, Tenaya and Mr. Blue may be deemed to beneficially own, and to have the power to vote or direct the vote, or dispose or direct the disposition of, all of the Common Shares beneficially owned by Synchron. The filing of this Schedule 13D should not be construed as an admission that any Reporting Person is the beneficial owner of any of the shares of Common Shares that such Reporting Person may be deemed to beneficially own.

Other than the transactions described Item 3 above, the Reporting Persons have not been involved in any transactions involving the securities of the Issuer in the last 60 days.

Except as otherwise indicated above, no other persons are known that have the right to receive or the power to direct the receipt of dividends from, or the proceeds of sale of, such securities.

Not applicable.

Item 6 of Amendment No. 4 is hereby incorporated by reference in its entirety.

Item 7 of Amendment No. 4 is hereby incorporated by reference in its entirety.